In 2015, Johns Hopkins scientists proved that scleroderma is often a casualty of war: it is the unfortunate consequence of the body’s battle to ﬁght off cancer. We have since learned much more about the complex, bidirectional relationship between cancer and autoimmunity. It is a tale told by antibodies: a paraneoplastic disease, in which naturally occurring anti-tumor immune responses lead to autoimmunity.
In this edition of LEAP Rounds, Dr. Ami Shah discusses target cancer screening at the interface of scleroderma and cancer.
Receive the Latest News from Johns Hopkins Rheumatology
Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.